ADAMTSL5是表观遗传激活基因,促进肝细胞癌肿瘤发生与耐药
该研究探讨分泌糖蛋白ADAMTSL5在肝细胞癌中的作用,发现其基因体CpG岛高甲基化与表达升高相关,ADAMTSL5缺失抑制体内外肿瘤特性并增加对索拉非尼、仑伐替尼、瑞戈非尼及贝姆森替尼的敏感性,提示其作为肿瘤发生与耐药主调控因子的潜力。
要点
- ADAMTSL5在人和小鼠肝细胞癌中基因体CpG岛高甲基化且表达升高。
- 靶向ADAMTSL5抑制肝癌细胞体内外肿瘤特性,过表达则赋予致瘤性。
- ADAMTSL5缺失降低MET、EGFR等受体酪氨酸激酶表达/磷酸化并增敏多种药物。
核心结论
- ADAMTSL5在肝细胞癌中表达升高,维持关键致癌信号通路功能,可能是肿瘤发生与耐药的主调控因子。
研究设计与样本
- 研究通过亚硫酸氢盐测序和公共数据分析评估ADAMTSL5甲基化状态,并在小鼠模型和患者样本中检测RNA和蛋白表达。
- 在细胞和体内模型中进行功能研究,包括ADAMTSL5缺失与临床相关药物反应性的关联。
主要发现
- 小鼠和人类肝细胞癌中ADAMTSL5基因体CpG岛高甲基化,与ADAMTSL5表达升高相关。
- 靶向ADAMTSL5在体外和体内干扰肝细胞癌细胞的致瘤特性,而过表达赋予前肿瘤肝细胞致瘤性。
- ADAMTSL5缺失降低MET、EGFR、PDGFRβ、IGF1Rβ或FGFR4的表达和/或磷酸化水平。
- ADAMTSL5缺失显著增加肝细胞癌细胞对索拉非尼、仑伐替尼和瑞戈非尼的敏感性,并大幅增加AXL表达及对贝姆森替尼的敏感性。
临床怎么用
- ADAMTSL5可能作为肝细胞癌的潜在标志物和药物靶点,其缺失可增敏索拉非尼、仑伐替尼、瑞戈非尼及贝姆森替尼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The tumour microenvironment shapes tumour growth through cellular communications that include both direct interactions and secreted factors. The aim of this study was to characterize the impact of the secreted glycoprotein ADAMTSL5, whose role in cancer has not been previously investigated, on hepatocellular carcinoma (HCC). METHODS: ADAMTSL5 methylation status was evaluated through bisulfite sequencing, and publicly available data analysis. ADAMTSL5 RNA and protein expression were assessed in mouse models and HCC patient samples and compared to data from published datasets. Functional studies, including association of ADAMTSL5 depletion with responsiveness to clinically relevant drugs, were performed in cellular and in vivo models. Molecular alterations associated with ADAMTSL5 targeting were determined using proteomics, biochemistry, and reverse-transcription quantitative PCR. RESULTS: Methylome analysis revealed hypermethylated gene body CpG islands at the ADAMTSL5 locus in both mouse and human HCC, correlating with higher ADAMTSL5 expression. ADAMTSL5 targeting interfered with tumorigenic properties of HCC cells in vitro and in vivo, whereas ADAMTSL5 overexpression conferred tumorigenicity to pre-tumoural hepatocytes sensitized to transformation by a modest level of MET receptor expression. Mechanistically, ADAMTSL5 abrogation led to a reduction of several oncogenic inputs relevant to HCC, including reduced expression and/or phosphorylation levels of receptor tyrosine kinases MET, EGFR, PDGFRβ, IGF1Rβ, or FGFR4. This phenotype was associated with significantly increased sensitivity of HCC cells to clinically relevant drugs, namely sorafenib, lenvatinib, and regorafenib. Moreover, ADAMTSL5 depletion drastically increased expression of AXL, accompanied by a sensitization to bemcentinib. CONCLUSIONS: Our results point to a role for ADAMTSL5 in maintaining the function of key oncogenic signalling pathways, suggesting that it may act as a master regulator of tumorigenicity and drug resistance in HCC. LAY SUMMARY: The environment of cancer cells has profound effects on establishment, progression, and response of a tumour to treatment. Herein, we show that ADAMTSL5, a protein secreted by liver cancer cells and overlooked in cancer so far, is increased in this tumour type, is necessary for tumour formation and supports drug resistance. Adamtsl5 removal conferred sensitivity of liver cancer cells to drugs used in current treatment. This suggests ADAMTSL5 as a potential marker in liver cancer as well as a possible drug target.
引用
- Arechederra M, Bazai SK, Abdouni A, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2020. PMID: 33197513. doi:10.1016/j.jhep.2020.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。